Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind Placebo Controlled Study With Aminophylline to Attenuate the Side Effect Profile of Regadenoson in Patients Undergoing Myocardial Perfusion Imaging.

NCT01250496 is registered in ClinicalTrials.gov with Rush University Medical Center as lead sponsor.

NCT NCT01250496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01250496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind Placebo Controlled Study With Aminophylline to Attenuate the Side Effect Profile of Regadenoson in Patients Undergoing Myocardial Perfusion Imaging.
Lead sponsor
Rush University Medical Center
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2010
Completion date
November 30, 2011
Enrollment
248 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients being assessed with nuclear stress testing of the heart using the stress agent regadenoson, lexiscan